Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 499 adults across four groups. Two groups received a dummy treatment (placebo) for the first 24 weeks before switching to upadacitinib (either 15 mg or 30 mg daily), while the other two groups received upadacitinib from the start at those same doses. The trial was studying upadacitinib as a treatment for rheumatoid arthritis — a condition that causes joint pain, swelling and stiffness. The main things being measured at 12 weeks were: how many participants had at least a 20% improvement across several markers of joint disease activity (called an ACR20 response), and how many reached a "low disease activity" level on a standard scoring tool (called DAS28-CRP). The reported data shows that at 12 weeks, around 28% of participants in the placebo group met the ACR20 response (meaning improvement of at least 20% across key joint measures), compared with about 65% in the 15 mg upadacitinib group and 56% in the 30 mg group. For the low disease activity measure, roughly 14% of placebo participants reached that threshold, compared with about 43% in the 15 mg group and 42% in the 30 mg group. Among the additional measures tracked, the reported data shows that the upadacitinib groups also had larger average reductions in the DAS28-CRP disease activity score and in a self-reported difficulty-with-daily-tasks score (HAQ-DI), as well as larger average improvements in a physical quality-of-life score (SF-36 PCS), compared with the placebo group. Around 12% of placebo participants met the stricter ACR50 response (50% improvement), versus roughly 34% and 36% in the 15 mg and 30 mg upadacitinib groups respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 40875187) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Rheumatoid Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with rheumatoid arthritis (RA) for at least 3 months.
- You have been treated with at least one biological medication (a type of advanced drug for RA) for at least 3 months, but your RA is still active, or you had to stop taking it because of side effects or it was not well tolerated.
- You have been taking a conventional RA medication (such as methotrexate, sulfasalazine, hydroxychloroquine, chloroquine, or leflunomide) for at least 3 months, and your dose has stayed the same for at least 4 weeks before starting the trial — you may take up to two of these medications at the same time, except methotrexate and leflunomide cannot be taken together.
- You have at least 6 swollen joints and at least 6 tender joints at your screening and baseline appointments.
- A blood test shows that your inflammation marker (called hsCRP) is at or above a certain level (3 mg/L) at your screening appointment.
Who may not be able to join:
- You have previously taken any JAK inhibitor medication, such as tofacitinib, baricitinib, or filgotinib (a specific type of RA drug).
- You have a history of any type of arthritis that started before the age of 17, or you currently have a joint or inflammatory condition other than RA — such as gout, lupus, psoriatic arthritis, ankylosing spondylitis, reactive arthritis, scleroderma, fibromyalgia with current active symptoms, or several other related conditions (confirm with trial site for the full list) — although having secondary Sjögren's Syndrome is allowed.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: AbbVie Inc., AbbVie
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12; Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.